See every side of every news story
Published loading...Updated

Bemarituzumab Elicits Positive Overall Survival in FGFR2b-Positive First-Line Gastric Cancer

Summary by Pharmacy Times
The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Monday, June 30, 2025.
Sources are mostly out of (0)

Similar News Topics